Triethylenemelamine: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
'''Triethylenemelamine''' ( | {{Short description|A chemical compound used in cancer treatment}} | ||
{{Chembox | |||
| ImageFile = Triethylenemelamine.png | |||
| ImageSize = 250px | |||
| ImageAlt = Structural formula of Triethylenemelamine | |||
}} | |||
'''Triethylenemelamine''' (TEM) is a chemical compound that has been used in the treatment of cancer. It belongs to the class of alkylating agents, which work by interfering with the DNA replication process in cancer cells, thereby inhibiting their growth and proliferation. | |||
==Chemical Properties== | ==Chemical Properties== | ||
Triethylenemelamine is a | Triethylenemelamine is a synthetic compound with the chemical formula C<sub>9</sub>H<sub>12</sub>N<sub>6</sub>. It is a derivative of melamine and is characterized by the presence of three ethyleneimine groups attached to the melamine core. This structure allows it to form cross-links with DNA, disrupting the cell cycle. | ||
==Medical Use== | |||
Triethylenemelamine was primarily used as a chemotherapeutic agent. It was one of the early alkylating agents introduced for cancer treatment. Its mechanism of action involves the alkylation of DNA, which leads to the formation of cross-links between DNA strands. This prevents the DNA from being properly replicated, ultimately leading to cell death. | |||
== | ==History== | ||
The development of triethylenemelamine as a cancer treatment began in the mid-20th century. It was part of a broader effort to find effective chemical agents that could target rapidly dividing cancer cells. Although it showed promise in early studies, its use has declined with the development of more effective and less toxic alternatives. | |||
==Side Effects== | ==Side Effects== | ||
Like many alkylating agents, triethylenemelamine can cause a range of side effects. These may include nausea, vomiting, bone marrow suppression, and increased risk of infection. Due to these potential adverse effects, its use is carefully monitored in clinical settings. | |||
== | ==Related Compounds== | ||
Triethylenemelamine is related to other alkylating agents such as [[cyclophosphamide]] and [[chlorambucil]]. These compounds share a similar mechanism of action but may differ in their specific applications and side effect profiles. | |||
== | ==Related Pages== | ||
* [[Alkylating agent]] | |||
* [[Chemotherapy]] | |||
* [[Cancer treatment]] | |||
[[Category:Alkylating agents]] | [[Category:Alkylating agents]] | ||
[[Category:Chemotherapy]] | |||
Revision as of 15:46, 9 February 2025
A chemical compound used in cancer treatment
| Chemical Compound | |
|---|---|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider ID | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| Properties | |
| Chemical Formula | |
| Molar Mass | |
| Appearance | |
| Density | |
| Melting Point | |
| Boiling Point | |
| Hazards | |
| GHS Pictograms | [[File:|50px]] |
| GHS Signal Word | |
| GHS Hazard Statements | |
| NFPA 704 | [[File:|50px]] |
| References | |
Triethylenemelamine (TEM) is a chemical compound that has been used in the treatment of cancer. It belongs to the class of alkylating agents, which work by interfering with the DNA replication process in cancer cells, thereby inhibiting their growth and proliferation.
Chemical Properties
Triethylenemelamine is a synthetic compound with the chemical formula C9H12N6. It is a derivative of melamine and is characterized by the presence of three ethyleneimine groups attached to the melamine core. This structure allows it to form cross-links with DNA, disrupting the cell cycle.
Medical Use
Triethylenemelamine was primarily used as a chemotherapeutic agent. It was one of the early alkylating agents introduced for cancer treatment. Its mechanism of action involves the alkylation of DNA, which leads to the formation of cross-links between DNA strands. This prevents the DNA from being properly replicated, ultimately leading to cell death.
History
The development of triethylenemelamine as a cancer treatment began in the mid-20th century. It was part of a broader effort to find effective chemical agents that could target rapidly dividing cancer cells. Although it showed promise in early studies, its use has declined with the development of more effective and less toxic alternatives.
Side Effects
Like many alkylating agents, triethylenemelamine can cause a range of side effects. These may include nausea, vomiting, bone marrow suppression, and increased risk of infection. Due to these potential adverse effects, its use is carefully monitored in clinical settings.
Related Compounds
Triethylenemelamine is related to other alkylating agents such as cyclophosphamide and chlorambucil. These compounds share a similar mechanism of action but may differ in their specific applications and side effect profiles.
